Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease

  • J. T. Greenamyre
Full Papers

DOI: 10.1007/BF01245235

Cite this article as:
Greenamyre, J.T. J. Neural Transmission (1993) 91: 255. doi:10.1007/BF01245235


Current antiparkinsonian therapies focus on either replacing dopamine via precursor (L-DOPA) administration, or directly stimulating postsynaptic dopamine receptors with dopamine agonists. Unfortunately, this approach is associated with numerous side effects and these drugs lose efficacy with disease progression. This article reviews recent evidence which suggests that negative modulation of glutamatergic neurotransmission has antiparkinsonian effects in a variety of rodent and primate models of parkinsonism. The pronounced synergism between dopaminergic agents and glutamate receptor antagonists may provide a means of using very low doses of the two drug classes in concert to treat Parkinson's disease effectively and minimize dose-related drug side effects.


Parkinson's disease glutamate receptor antagonists NBQX CPP AMPA receptor NMDA receptor subthalamic nucleus 

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • J. T. Greenamyre
    • 1
  1. 1.Departments of Neurology, Neurobiology and Anatomy, and PharmacologyUniversity of RochesterRochesterUSA

Personalised recommendations